Funding for this research was provided by:
Korea National Institute of Health (HI14C3418)
Received: 9 April 2019
Accepted: 2 October 2019
First Online: 26 November 2019
Ethics approval and consent to participate
: The study was approved by the local committee on the use of human samples for experimental studies of the Samsung Medical Center (SMC), Seoul, Republic of Korea (IRB file #201004004). Written informed consents were provided by the participants prior to enrollment. All experimental methods abided by the Helsinki Declaration.
: Not applicable
: Do-Hyun Nam is the CEO of AimedBio Inc. and owns shares of AimedBio Inc. which owns IPs for Avatascan. The other authors declare that they have no competing interests.